It found that the antibody response of current vaccines could fail against variants. Another French firm, Lyon-based Osivax, is also working on a T cell shot, promising a "universal" vaccine that would be effective against any potential variant. Other questions involve the extent to which the body will be able to fight the virus with a T cell-based response. Peyroles confirmed that OSE's vaccine, should it prove effective in trials, is indeed meant as a way to strengthen current inoculations. He added that T cell vaccines could offer protection to people who have difficulties developing antibodies due to other ailments such as diabetes or cancer.

Source: Dhaka Tribune May 08, 2021 08:48 UTC